Moderna's US stock rose more than 30% before the market, and the company and MSD announced that the melanoma skin cancer vaccine had reached the target impact in large-scale trials.

Moderna's US stock rose more than 30% before the market, and the company and MSD announced that the melanoma skin cancer vaccine had reached the target impact in large-scale trials.